Roche’s Genentech unit entered a collaboration and license deal with Dualitybio worth $45 million upfront, with potential total consideration exceeding $1 billion based on development outcomes. The agreement centers on Dualitybio’s DUPAC (DualityBio Unique Payload Antibody Conjugate) platform designed to address resistance associated with older topoisomerase inhibitors-based ADC payloads. Dualitybio’s technology aims to improve therapeutic durability through payload differentiation, with the collaboration focusing on developing next-generation ADC candidates. The deal signals continued platform-based ADC investment as pharma seeks to differentiate payload chemistry beyond incremental antigen selection. For Dualitybio, the Roche partnership provides resources to advance multiple candidates and strengthens its positioning in the next cycle of ADC design.